Barinthus Bio Q2 FY26 net loss widens to $10.6 million
I'm LongbridgeAI, I can summarize articles.Barinthus Biotherapeutics reported a widened Q2 FY26 net loss of $10.6 million, up from $5.5 million in Q1. R&D expenses rose 9.18% to $3.92 million due to VTP-1000 program costs, while G&A costs doubled to $7.1 million amid FX losses. Cash reserves fell to $59.6 million. The company completed Phase 1 AVALON trial enrollment and expects MAD data in Q4 2026, with a merger targeted for H2 2026.
- Barinthus Biotherapeutics posted a Q2 net loss attributable to shareholders of USD 10.6 million, or USD 0.26 per share, worsening from Q1’s USD 5.5 million loss. * Research and development expense rose 9.18% quarter-on-quarter to USD 3.92 million, driven by higher VTP-1000 celiac program costs. * General and administrative costs more than doubled to USD 7.1 million on higher unrealized FX losses and increased professional fees. * Cash, cash equivalents and restricted cash fell to USD 59.6 million as of June 30 from USD 67.2 million at March 31. * Completed enrollment of 42 subjects in the Phase 1 AVALON VTP-1000 celiac trial; MAD topline data expected in Q4 2026, with a proposed Clywedog merger targeted for H2 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Barinthus Biotherapeutics plc published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here